Martin NE, Mucci LA, Loda M, Depinho RA (2011) Prognostic determinants in prostate cancer. Cancer J 17(6):429–437

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al (2011) SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–17

Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB et al (2009) Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 101(18):1280–3

Article  PubMed  PubMed Central  Google Scholar 

Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW (2008) External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 72(2):396–400

Article  PubMed  Google Scholar 

Sun Z, Ju Y, Han F, Sun X, Wang F (2018) Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer. J Clin Lab Anal 32(3):e22277. https://doi.org/10.1002/jcla.22277

Article  CAS  PubMed  Google Scholar 

Santotoribio JD, Jimenez-Romero ME (2019) Serum biomarkers of inflammation for diagnosis of prostate cancer in patients with nonspecific elevations of serum prostate specific antigen levels. Transl Cancer Res 8(1):273–278

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pittoni P, Colombo MP (2012) The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 72(4):831–5

Article  CAS  PubMed  Google Scholar 

Globa T, Saptefrţi L, Ceauşu RA, Gaje P, Cimpean AM, Raica M (2014) Mast cell phenotype in benign and malignant tumors of the prostate. Pol J Pathol 65:147–153

Article  CAS  PubMed  Google Scholar 

Rao V, Garudadri G, Shilpa AS, Fonseca D, Sudha SM, Sharma R et al (2018) Validation of the WHO 2016 new Gleason score of prostatic carcinoma. Urol Ann 10:324–329

Article  PubMed  PubMed Central  Google Scholar 

Amin K (2012) The role of mast cells in allergic inflammation. Respir Med 106:9–14

Article  PubMed  Google Scholar 

da Silva EZ, Jamur MC, Oliver C (2014) Mast cell function: a new vision of an old cell. J Histochem Cytochem 62(10):698–738

Article  PubMed  Google Scholar 

Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M et al (2009) Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 69(9):976–981

Article  CAS  PubMed  Google Scholar 

Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J et al (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177(2):1031–1041

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Z, Yue L, Xu Z, Zeng S, Ma Y, Li Z et al (2018) The effect of mast cells on the biological characteristics of prostate cancer cells. Cent Eur J Immunol 43(1):1–8

Article  PubMed  PubMed Central  Google Scholar 

Rosenberg A, Mathew P (2013) Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 22(6):787–94

Article  CAS  PubMed  Google Scholar 

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A et al (2019) Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7–18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harris KS, Shi L, Foster BM, Mobley ME, Elliott PL, Song CJ et al (2021) CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance. Sci Rep 11(1):1465. https://doi.org/10.1038/s41598-021-81126-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foroozan M, Roudi R, Abolhasani M, Gheytanchi E, Mehrazma M (2017) Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. Pathol Res Pract 213(6):612–618

Article  CAS  PubMed  Google Scholar